Clinical Trials Browser

Breast Neoplasms

NCT02917421 2026-04-17

ART

Phase 1/2 Active not recruiting

88 enrolled 10 charts

Breast

Breast Neoplasms

NCT03495115 2026-04-17

Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening

Phase NA Completed

460 enrolled 4 charts

Breast

Breast Neoplasms

NCT03157128 2026-04-16

LIBRETTO-001

Phase 1/2 Active not recruiting

857 enrolled 24 charts 6 FDA

BreastCNSEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT04267796 2026-04-16

Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women

Phase NA Active not recruiting

40 enrolled 9 charts

Breast

Breast Neoplasms

NCT02095184 2026-04-15

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

Phase NA Terminated

42 enrolled 13 charts

Breast

Breast Neoplasms

NCT03935282 2026-04-15

AH-HA

Phase NA Completed

645 enrolled 43 charts

BreastGastrointestinalGenitourinaryGynecologicLymphoid

Breast Neoplasms, Cardiovascular Diseases, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Health Behavior, Endometrial Neoplasms

Clinical Trials

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

ART

Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening

LIBRETTO-001

Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

AH-HA

TAILORx

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

FINER

A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer

COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation

TRANSCENDER

Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Promoting Informed Choice for Breast Cancer Screening

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

HER2CLIMB-04

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening

EMPRESS

CONFIRM

VERITAC-2

Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer

INAVO120

CARABELA

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

FELINE

Breathwork App for Cancer Survivors

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

A Study of Serum Folate Levels in Patients Treated With Olaparib

DB-06

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Breast-47

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]